2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Schmid P, Lipatov O, Im S, Goncalves A, Muñoz-Couselo E, Lee K, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Mejia J, Zhou X, Haiderali A, Nguyen A, Cortes J, Winer E. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. European Journal Of Cancer 2023, 195: 113393. PMID: 37976633, DOI: 10.1016/j.ejca.2023.113393.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerCombined positive scoreMetastatic triple-negative breast cancerPD-L1 combined positive scoreHealth-related qualityBreast cancerQLQ-C30 functional scalesTumor PD-L1 expressionGHS/QoLNausea/vomitingPD-L1 expressionStart of treatmentHRQoL resultsEligible patientsHRQoL analysisOverall survivalSystemic therapyClinical outcomesFunctional scalesPhysician's choicePatientsChemotherapyFirst onsetCountry guidelinesMedian TTD
2017
Survival benefit needed to undergo chemotherapy: Patient and physician preferences
Vaz‐Luis I, O'Neill A, Sepucha K, Miller KD, Baker E, Dang CT, Northfelt DW, Winer EP, Sledge GW, Schneider B, Partridge AH. Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 2017, 123: 2821-2828. PMID: 28323331, PMCID: PMC5517352, DOI: 10.1002/cncr.30671.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAttitude of Health PersonnelAttitude to HealthBevacizumabBreast NeoplasmsChemotherapy, AdjuvantClinical Trials, Phase III as TopicCyclophosphamideDoxorubicinFemaleHumansMastectomyMastectomy, SegmentalMiddle AgedPaclitaxelPatient PreferencePhysiciansQuality of LifeRandomized Controlled Trials as TopicRisk AssessmentSurveys and QuestionnairesSurvival RateTumor BurdenConceptsMonths of chemotherapyModest survival benefitSurvival benefitAdjuvant chemotherapyEarly-stage breast cancerContemporary adjuvant chemotherapyPhase 3 trialBreast cancer patientsStage breast cancerQuality of lifeMonths of benefitsAdjuvant cyclophosphamideAdjuvant doxorubicinChemotherapy regimenMost patientsUndergoing ChemotherapyCancer patientsPatient preferencesBreast cancerModest benefitOld regimenChemotherapyPatientsPhysician's choiceSerial surveys
2016
KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC).
Winer E, Dang T, Karantza V, Su S. KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC). Journal Of Clinical Oncology 2016, 34: tps1102-tps1102. DOI: 10.1200/jco.2016.34.15_suppl.tps1102.Peer-Reviewed Original Research